Navigation Links
Arcion Therapeutics' Topical Pain Candidate, ARC-4558, Significantly Reduces Pain Caused by Diabetic Neuropathy
Date:5/7/2009

-Clinical Data Presented at American Pain Society Annual Meeting-

BALTIMORE, May 7 /PRNewswire/ -- Arcion Therapeutics, Inc., a venture backed clinical stage biotechnology company that develops pain therapies, today announced the presentation of data demonstrating that its lead candidate, ARC-4558, significantly reduced pain caused by diabetic neuropathy in a double-blind, placebo-controlled trial. The abstract will be presented in a poster session on May 8th from 4:00-5:30 PM at the American Pain Society Annual Meeting, held May 7-9 in San Diego. ARC-4558 is a 0.1% gel formulation of clonidine hydrochloride for topical administration. Arcion is currently conducting a Phase 2b clinical trial of ARC-4558 for the treatment of painful diabetic neuropathy (PDN).

According to the abstract, patients receiving 0.1% clonidine gel reported significantly greater reductions in pain when compared to placebo (p=0.015). This improvement was demonstrated in the first week of the study (p=0.003). Participants in the 0.2% group did not differ from those in the placebo group, though a trend was observed (p=0.054). The 0.2% results may have been due to the fact that this group received 23% less gel in order to avoid higher systemic dosing. Consistent with this, clonidine blood levels in the 0.2% group were the same as that in the 0.1% group. Responder analysis revealed that 47.2% of patients across both treatment groups combined had 30% or more pain relief compared to 29.3% in the placebo group (p=0.031). Blood levels of clonidine varied from non-detectable to levels several-fold below the threshold required to treat hypertension (the original indication for clonidine). Patients with detectable clonidine in the blood experienced significantly greater pain reduction than patients in whom clonidine was not detected (p<0.05).

"These data demonstrate that ARC-4558 may offer a new approach to treating the pain associated with diabetic neuropathy. By applying the drug topically to the area of pain, systemic exposure is minimized, and hence, systemic side effects appear to be minimal. Moreover, this approach may be complementary to systemic approaches. We are now in the midst of an additional randomized, controlled Phase 2b trial to confirm the safety and efficacy of topical clonidine," said James Campbell, M.D., President and CEO of Arcion. "ARC-4558 is a result of Arcion's expertise in developing differentiated drugs through our understanding of the underlying biology of neuropathic pain."

Previously published research has shown that in neuropathic pain conditions such as PDN, the signal that triggers pain actually arises at the level of the skin. The data reported today for ARC-4558 provide further rationale for applying therapies topically at the site of the pain. From a treatment standpoint, this approach has the potential to offer multiple benefits over orally bioavailable or patch-based treatments including more convenient application, uniform coverage of the affected site, lower systemic side-effects and fewer drug interactions.

The abstract, titled, "Topical clonidine gel (ARC-4558) reduces pain caused by diabetic neuropathy: Results of a multicenter, placebo-controlled clinical trial," was authored by Claudia M. Campbell, Ph.D., Johns Hopkins School of Medicine; Bruce Stouch, Ph.D., BCS Consulting; Kerrie Brady, M.S., M.B.A., Arcion Therapeutics; Bill Schmidt, Ph.D., NorthStar Consulting LLC; and James Campbell, M.D., Johns Hopkins School of Medicine and Arcion Therapeutics.

About the Trial

The double-blind, placebo-controlled trial included 166 patients with chronic, bilateral, lower extremity, painful diabetic neuropathy. Patients were randomized to receive 0.1% or 0.2% topical clonidine gel or placebo gel, and remained on their existing pain management treatments. The gel was applied to both feet twice daily for the first two weeks and three times a day for six weeks. Participants rated their pain throughout the study.

About Painful Diabetic Neuropathy (PDN)

Diabetic neuropathy is one of the most common complications of diabetes mellitus that is associated with a number of painful conditions. According to 2008 estimates by the Centers for Disease Control and Prevention, nearly 24 million people in the United States are affected by diabetes. Given a conservative estimate that 15% of people with diabetes have painful neuropathies, approximately 3.6 million Americans experience PDN. PDN is thought to result from chronic hyperglycemia, which can lead to diabetic microvascular injury involving small blood vessels that supply nerves (vasa nervorum), particularly the sensory, motor and autonomic nerve fibers. Patients with PDN often experience debilitating pain symptoms that affect day-to-day functioning and quality of life.

About Arcion

Arcion Therapeutics applies breakthroughs in neuroscience to advance the treatment of chronic pain. The company focuses on innovative topical treatments to provide pain relief with convenient application and reduced systemic side effects. Arcion's product pipeline comprises multiple candidates to treat neuropathic pain.


'/>"/>
SOURCE Arcion Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Trius Therapeutics Announces Presentations Featuring Torezolid Antibiotic at the 19th European Congress of Clinical Microbiology and Infectious Diseases
2. Hyperion Therapeutics Receives Orphan Drug Designation for HPN-100 for the Treatment of Urea Cycle Disorders
3. Sirion Therapeutics Announces Clinical Data Presentations at the 2009 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
4. Intarcia Therapeutics, Inc. Announces Completion of Enrollment of ITCA 650 Phase 1b Study for the Treatment of Type 2 Diabetes
5. Hyperion Therapeutics Announces Results for Phase II Study in Urea Cycle Disorders
6. Amicus Therapeutics Announces Issuance of New Plicera(TM) Composition of Matter Patent
7. Vantia Therapeutics Pipeline Continues to Mature
8. Calixa Therapeutics Announces Positive Phase 1 Results for CXA-101, a Novel Intravenous Cephalosporin Antibiotic with Excellent Anti-Pseudomonal Activity
9. Oxygen Biotherapeutics, Inc. Receives Letter From FDA Outlining Path Forward to Resume Oxycyte Clinical Trials in TBI in U.S.A.
10. Alba Therapeutics Corporation Announces the Next Clinical Trial of Its Lead Compound, Larazotide Acetate and Promotions
11. InteKrin Therapeutics Announces Enrollment Completion of 360 Patient, 24 week Phase 2b Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/22/2017)... 22, 2017 Hologic, Inc. (Nasdaq: ... acquisition of Cynosure, Inc., a leader in medical aesthetics ... "We are pleased to complete our acquisition ... Michael Davin and the entire Cynosure team to ... medical aesthetics market," said Steve MacMillan , Hologic,s ...
(Date:3/22/2017)... -- TFS is pleased to announce the appointment of ... two global executive positions in Medical Affairs and Clinical Development. Dr. ... and will report to Dr. Montse Barceló , Chief Operating ... ... of medical and scientific expertise gained across leading biopharmaceutical companies and ...
(Date:3/22/2017)... 22, 2017  Levine Cancer Institute today launched ... designed to address lung cancer diagnosis, treatment and ... The mobile lung unit is the first-of-its-kind to ... treatment interventions through integrated mobile technology, traditional treatment ... barriers and a lack of public transportation are ...
Breaking Medicine Technology:
(Date:3/22/2017)... ... ... College basketball surges to its peak during the March Madness NCAA tournament, but ... to be foster parents. Through a televised spot, Coach Self is inviting adults to ... abuse, neglect and other family challenges. People who respond to Self’s call to community ...
(Date:3/22/2017)... ... ... HumanHaus is proud to announce the launch of its newest invention on crowdfunding ... invented, but our customers today are busy, energetic, multi-taskers that live in a smarter ... and retired that want to travel. The Sweep&Stand is a self-standing broom ...
(Date:3/22/2017)... ... ... NYC Chiropractor Dr. Steven Shoshany recently helped host a seminar at his cutting edge ... focused on a new protocol for treating pain. Dr. Shoshany is among the first ... the first seminar in the country was hosted at his Integrated Chiropractic Practice. ...
(Date:3/22/2017)... , ... March 22, 2017 , ... Sharon Kleyne is ... more than two decades ago to research evaporation of earth’s and the body’s water ... better health. Also the host of the nationally syndicated radio program, The Sharon Kleyne ...
(Date:3/22/2017)... ... March 22, 2017 , ... The International Association of ... specialists and other medical professionals caring for those suffering from the full spectrum ... iaedp Symposium at the Green Valley Resort in Las Vegas, March 22 - ...
Breaking Medicine News(10 mins):